trending Market Intelligence /marketintelligence/en/news-insights/trending/2eedgi9bwnexgeajxf1nzq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Halozyme appoints former Bristol-Myers exec as chief commercial officer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Halozyme appoints former Bristol-Myers exec as chief commercial officer

Halozyme Therapeutics Inc. appointed Benjamin Hickey as chief commercial officer, effective Sept. 10.

The San Diego-based company said Hickey will build and execute the commercial strategy for its oncology portfolio, beginning with the investigational drug pegvorhyaluronidase alfa, or PEGPH20, if approved.

Hickey previously served as general manager for U.K. and Ireland at Bristol-Myers Squibb Co. During his 17-year career at Bristol-Myers, Hickey also served as vice president of marketing for immuno-oncology, where he led the commercialization of blockbuster cancer drug Yervoy and oversaw the launch preparedness of Opdivo, another blockbuster cancer drug.